Alite F, et al. - Researchers assessed the role of angiotensin-converting enzyme inhibitors (ACEi) in diminishing rates of symptomatic (grade ≥2) pneumonitis in the setting of lung stereotactic body radiation therapy (SBRT), using univariate and multivariate analysis and Kaplan-Meier method. The observed overall 1-year rate of symptomatic pneumonitis was 13.2%. For ACEi users vs nonusers, the observed 1-year rate of symptomatic pneumonitis was 4.2% vs 16.3% respectively. A significant link between ACEi use and decreased risk of clinical pneumonitis was observed after controlling for clinicopathologic characteristics and dosimetric endpoints in multivariate analysis. No significant associations of angiotensin receptor blockers or other bronchoactive medications with the development of pneumonitis were evident. Overall, for achieving diminished rates of symptomatic pneumonitis in the setting of lung SBRT, incidental concurrent use of ACEi was proved efficacious.